Our Science and Technology
Rooted in a Deep Understanding of Genetics
The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.
WHO WE ARE
Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.
Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.
We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs.
We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.
We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.
JOIN OUR TEAM
Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.
LATEST NEWS FEED
Sign Up for News Alerts
For the latest on Ionis news and developments
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 2, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 H.C.
– Up to 72% (p0.0001) placebo-adjusted mean reduction in fasting triglycerides – – 85% (p=0.0002) reduction in acute pancreatitis events, the first and only time achieved for the treatment of sHTG – – Favorable safety and tolerability profile – – sNDA submission planned by end of year – – Ionis to
<p>- DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control - - Offers longest dosing option for HAE, with dosing every 4 or 8 weeks - - Compelling profile supported by recently published switch data - - Ionis’ second independent launch in just nine</p>
Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).